Figure 7.

In vivo treatment of CS SW1353-bearing mice

BALB/c nu/nu mice with established subcutaneous xenografts were intravenously administrated with either targeted RGD4C.PDP-sTRAIL or non-targeted PDP-sTRAIL at a dose of 5 × 10¹⁰ TU per mouse, twice a week for 14 days. (A) Representative tumor-bearing mice, from all experimental groups, imaged using the In Vivo BLI System at day 0 (before treatment initiation) and day 6 and day 14 after vector administration. (B) Tumor luminescence values shown as fold change between pre-treatment day 0 and post-vector treatment day 14. (C) Microscopic images of the H&E-stained tumors upon treatment with targeted RGD4C.PDP-sTRAIL or non-targeted PDP-sTRAIL. Scale bar, 20 μm. (D) Average weights of SW1353 tumor-bearing mice, from all experimental groups, measured on days 6, 10, and 14 after vector injection. (E) Evaluation of sTRAIL gene expression in tumors versus normal organs, from tumor-bearing mice, after intravenous administration of either targeted RGD4C.PDP-sTRAIL or non-targeted PDP-sTRAIL. Results are shown as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01.